Health Care [ 5/12 ] | Biotechnology [ 22/74 ]
NASDAQ | Common Stock
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia.
The company distributes its products through third-party distributors.
It has collaborations with F.
Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program.
It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States.
PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.34 Decreased by -42.33% | -0.65 Increased by +47.45% |
| Nov 7, 24 | -1.39 Increased by +21.02% | -1.44 Increased by +3.47% |
| Aug 8, 24 | -1.27 Increased by +52.26% | -1.05 Decreased by -20.95% |
| Apr 25, 24 | -1.20 Increased by +36.17% | -1.24 Increased by +3.23% |
| Feb 29, 24 | -0.24 Increased by +87.30% | 0.50 Decreased by -148.00% |
| Oct 26, 23 | -1.76 Decreased by -15.03% | -1.17 Decreased by -50.43% |
| Aug 3, 23 | -2.66 Decreased by -24.88% | -1.71 Decreased by -55.56% |
| Apr 27, 23 | -1.88 Decreased by -5.62% | -1.52 Decreased by -23.68% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 213.17 M Decreased by -30.58% | -65.89 M Increased by +57.71% | Decreased by -30.91% Increased by +39.08% |
| Sep 30, 24 | 196.79 M Increased by +0.11% | -106.65 M Increased by +19.79% | Decreased by -54.20% Increased by +19.88% |
| Jun 30, 24 | 186.70 M Decreased by -12.68% | -99.18 M Increased by +50.13% | Decreased by -53.12% Increased by +42.89% |
| Mar 31, 24 | 210.12 M Decreased by -4.66% | -91.58 M Increased by +34.10% | Decreased by -43.58% Increased by +30.88% |
| Dec 31, 23 | 307.06 M Increased by +83.41% | -155.79 M Increased by +8.83% | Decreased by -50.74% Increased by +50.30% |
| Sep 30, 23 | 196.58 M Decreased by -9.46% | -132.97 M Decreased by -21.64% | Decreased by -67.64% Decreased by -34.36% |
| Jun 30, 23 | 213.81 M Increased by +29.17% | -198.88 M Decreased by -30.77% | Decreased by -93.02% Decreased by -1.24% |
| Mar 31, 23 | 220.38 M Increased by +48.17% | -138.96 M Decreased by -9.65% | Decreased by -63.05% Increased by +26.00% |